Abstract
The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min. There is strong reason to anticipate that additional benefits will accrue with gemcitabine-based combination chemotherapy. Gemcitabine and CPT-11 are synergistic with many drugs and non-cross-resistant with each other. Rigorous clinical investigations will be performed in an effort to identify optimal drug sequence and schedules for these novel combinations.
| Original language | English |
|---|---|
| Pages (from-to) | 683-690 |
| Number of pages | 8 |
| Journal | Surgical Clinics of North America |
| Volume | 81 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |